Efficacy and safety of neoadjuvant pd-1 inhibitor combined with chemotherapy in locally advanced esophageal squamous-cell carcinoma: A meta-analysis

The main outcome measures of neoadjuvant chemotherapy combined with PD-1 inhibitor treatment were: major pathological response (MPR) rate of 46%, pathologic complete response (pCR) rate of 29%; secondary outcome measures were: objective response rate (ORR) of 66%, disease control rate (DCR) of 100%, surgical resection rate of 100%, and treatment-related adverse events (TRAEs) occurrence rate of 16%. Subgroup analysis results showed no significant difference in MPR rate between the camrelizumab group and the toripalimab group (P=0.21), but there was a statistically significant difference in pCR rate (P=0.04), with the pCR rate in the camrelizumab group (33%, 95% CI:27-40%) higher than that in the toripalimab group (19%, 95% CI:10-31%).Conclusion Neoadjuvant chemotherapy combined with PD-1 inhibitors in the treatment of locally advanced ESCC can bring survival benefits to patients and has an overall good safety profile.